Merck Recognizes Eurofins Viracor BioPharma with "Top Performer" Award

Eurofins Viracor BioPharma receives “Top Performer” Award from Merck, in recognition for their dedication and successful execution of the PCR assay validation supporting a recent Merck clinical development project.

We at Eurofins Viracor Biopharma are very proud to have received this award from the wonderful folks at Merck. We’ve been honored to partner with them on multiple development projects over the years, supporting their efforts to bring innovative therapy solutions to the world.

The award specifically recognizes our success with a challenging, year-long R&D project; the results of which will be used to support multiple future clinical trials. In addition to being an indication of their appreciation for the important contribution Eurofins Viracor made to this most recent study, the award further illustrates the trust and confidence that the dedicated people at Merck have in our expertise and ability to deliver on our promises.

Helping to advance the pioneering new treatments of our clients is what drives us at Eurofins Viracor, together with the knowledge that we are playing a valuable part in enhancing, and in some cases saving, the lives of people all over the world.

James Furbee, Business Development Director

Mark Wissel, Director R&D

Crystal Marti, Director of Lab Ops

Holly Lash, Associate Principal Scientist, Merck

Beth Arnold, Senior Director, Merck

Megan Hawkinson, Project Manager

Krista Arnett, Research Scientist III

Dan Shepherd, Director of Biopharma Operational Services